Biomedicine has its own set of guidelines for implementing emerging technology for human use, which is understandably conservative. Increased research has helped in the reformulation of existing drugs as well as the creation of new ones. Nanotechnology changes medicine’s toxicity, solubility, and bioavailability profile, among other items. However, there is still a long way to go in terms of full regulation, beginning with the development of consistent definitions across the board. The medicinal products come in a wide variety of forms and structures, and they’ve been used to treat a wide range of acute and chronic diseases. Furthermore, ongoing research is increasingly leading to the emergence of more sophisticated nanostructured designs, which necessitates a detailed understanding of pharmacokinetic and pharmacodynamic properties, which are determined by chemical composition and physicochemical properties, poses additional regulatory challenges.
